Drug-Eluting Stents Market Thumbnail Image

2021

Drug-Eluting Stents Market

Drug-Eluting Stents Market Size, Share, Competitive Landscape and Trend Analysis Report by Coating, Application and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

LS : Medical Devices & Supplies

Select an option
Author's: Trupti Wadekar| Sushant Terdale | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global drug-eluting stents market was valued at $6,382 million in 2019, and is projected to reach $8,777 million by 2027, registering a CAGR of 8.7% from 2020 to 2027.

Drug-eluting stent (DES) is a peripheral or coronary stent placed into narrowed, diseased peripheral, or coronary arteries that slowly release a drug to block cell proliferation. Drug-eluting stents are coated with medication, which is released (eluted) to prevent growth of scar tissues in arterial walls. Eluted drug helps arteries to remain smooth and exposed, which ensures adequate blood flow and decrease in chances of restenosis. DES is regarded as the gold standard for treatment of coronary heart disease, as it offers various benefits such as enhanced vessel healing, minimally invasive nature, and reduced need for prolonged dual antiplatelet therapy. Patients implanted with DES are recommended to use certain medications or drug therapy. This therapy helps to decrease the risk of in-stent thrombosis, owing to a comparatively slower healing process.

Drug-Eluting-Stents-Market,-2020-2027

Constant rise in geriatric population primarily drives growth of the drug-eluting stents market as geriatric population is at high risk of developing arterial disorders. In addition, unhealthy food habits, sedentary lifestyles, and lack of exercise increase the prevalence of atherosclerosis worldwide, which propels growth of the market. Moreover, rise in drug eluting stents product approvals and minimally-invasive techniques for DES placing augments growth of the drug eluting stent market. Furthermore, rise in prevalence of several cardiovascular diseases such as abnormal heart rhythms, heart attack, heart valve disease, congenital heart diseases, and heart failure function is expected to boost the growth of the market. However, stringent government regulations for product approval restricts growth of the market. Conversely, rise in potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, manufacturing and distributing companies drug-eluting stents have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply. 

Drug-eluting Stents Market Segmentation  

The global drug-eluting stents market is segmented on the basis of coating, application, end user, and region. On the basis of coating, the market is divided into polymer-based coating and polymer free coating. The polymer-based coating segment is further bifurcated into biodegradable and non-biodegradable. The polymer free coating segment is further divided into microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface. By application, the market is categorized into coronary artery disease and peripheral artery disease. By end user, the market is bifurcated into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Drug-Eluting Stents Market
By Coating
Your browser does not support the canvas element.

Polymer free coating segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Segment review 

Presently, on the basis of coating, the polymer free coating segment is the major revenue contributor, and is projected to grow significantly during the forecast period. High adoption of DES is attributed to lower in-stent restenosis rates, quicker drug eluting rate, and higher drug loading capacity of nanoporous surfaces. Moreover, polymer free coating offers advantages such as inflammatory issues produced by polymers used in stents can be avoided by excluding polymer coating completely and releasing anti-proliferative drug directly from the stent surface.

By application, the coronary artery disease segment is the major shareholder in the global drug-eluting stents market, owing to rise in prevalence of coronary artery disease, surge in adoption of drug-eluting stents, and increase in product approvals of drug-eluting stents in coronary artery disease treatment.  

Drug-Eluting Stents Market
By End User
Your browser does not support the canvas element.

Hospitals segment is projected as one of the most lucrative segment.

Snapshot of Asia-Pacific drug-eluting stents market  

Asia-Pacific presents lucrative opportunities for key players operating in the drug-eluting stents market, owing to increase in prevalence of coronary artery disease and peripheral artery disease, growth in patient awareness toward commercial availability of products, increase in geriatric population in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in drug-eluting stents products. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the drug-eluting stents market in the region.

The key players profiled in this report include Abbott Laboratories, Alvimedica, B. Braun Holding GmbH & Co. KG, Biosensors International Group, Biotronik Inc., Boston Scientific Corporation, Cook Group (Cook Medical), Medtronic Plc, Stentys SA, and Terumo Corporation.

Drug-Eluting Stents Market
By Region
2027
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 10.0% during 2020-2027.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the drug-eluting stents market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers drug-eluting stents market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global drug-eluting stents market growth.

Drug-Eluting Stents Market Report Highlights

Aspects Details
icon_5
By Coating
  • Polymer Based Coating
    • Biodegradable
    • Non-Biodegradable
  • Polymer Free Coating
    • Microporous Surface
    • Microstructured Surface
    • Slotted Tubular Surface
    • Nanoporous Surface
icon_6
By Application
  • Coronary Artery Disease
  • Peripheral Artery Disease
icon_7
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

B. BRAUN HOLDING GMBH & CO. KG, COOK GROUP (COOK MEDICAL), TERUMO CORPORATION, STENTYS SA, BIOTRONIK, INC., MEDTRONIC PLC., ALVIMEDICA, ABBOTT LABORATORIES, BOSTON SCIENTIFIC CORPORATION, BIOSENSORS INTERNATIONAL GROUP, LTD

Analyst Review

Drug-eluting stents are expandable tubes made up of metal inserted into arteries of patients suffering from atherosclerosis. These stents hold artery open to release a medication that prevents reoccurring of blockages and improves blood flow.

Rise in burden of cardiovascular diseases, rapid growth in aging population, surge in demand for minimally invasive procedures, increase in number of percutaneous coronary intervention (PCI) procedures, and technological advancements in drug-eluting stents are expected to drive growth of the drug-eluting stents market.

North America is expected to remain dominant during the forecast period, owing to increase in demand for drug-eluting stents in coronary artery disease and peripheral artery disease treatment, rise in geriatric population, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to increase in patient awareness toward cardiovascular disease treatment.

Author Name(s) : Trupti Wadekar| Sushant Terdale | Roshan Deshmukh
Frequently Asked Questions?

The total market value of Drug-Eluting Stents market is $6,381.76 million in 2019.

The forcast period for Drug-Eluting Stents market is 2020 to 2027

The market value of Drug-Eluting Stents market in 2020 is $4,893.80 million.

The base year is 2019 in Drug-Eluting Stents market

Top companies such as Boston Scientific Corporation, Abbott Laboratories, Medtronic Plc, Biotronik Inc., Terumo Corporation, Cook Group (Cook Medical), and B. Braun Holding GmbH & Co. KG held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

Polymer free coating segment is the most influencing segment owing to lower in-stent restenosis rates, quicker drug eluting rate, and higher drug loading capacity of nanoporous surfaces propel the market growth. Moreover, polymer free coating offers advantages such as inflammatory issues produced by polymers used in stents can be avoided by excluding polymer coating completely and releasing anti-proliferative drug directly from the stent surface.

Rise in prevalence of cardiovascular diseases such as congenital heart disease, abnormal heart rhythms, heart valve disease, heart attack, and heart failure is expected to drive growth of the market. In addition, technological advancements in drug eluting stents design and stent delivery systems is another major factor that boosts the market growth. Moreover, rise in number of product approvals and favorable reimbursement policies, coupled with high incidence rate of artery diseases also fuel growth of the drug-eluting stents market

Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 11.7%. This is due to increase in number of initiatives and enhanced investments from governments for the overall development of drug-eluting stents, and surge in prevalence of peripheral artery disease. Moreover, favorable reimbursement policies associated with cardiovascular disease treatment, high demand for drug delivery devices, and increase in public awareness towards the usage and benefits of these devices are the key reasons for the significant growth of the market

Drug-eluting stents (DES) are small tube like, semi-rigid device that aid in improving blood flow through arteries to heart by minimizing blockages.

Drug-Eluting Stents products used for treatment of coronary artery disease and peripheral artery disease.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Drug-Eluting Stents Market

Global Opportunity Analysis and Industry Forecast, 2020-2027